Introduction: . Most breast cancer-related deaths arise from triple-negative breast cancer (TNBC). Molecular heterogeneity, aggressiveness and the lack of effective therapies are major hurdles to therapeutic progress. Chimeric antigen receptor (CAR)-T cells have emerged as a promising immunotherapeutic strategy in TNBC. This approach combines the antigen specificity of an antibody with the effector function of T cells. Areas covered: This review examines the opportunities provided by CAR-T cell therapies in solid tumors. Emerging targets, ongoing clinical trials, and prospective clinical implications in TNBC are considered later. An emphasis is placed on the key challenges and possible solutions for this therapeutic approach. Expert opinion: A challenge for CAR-T cell therapy is the selection of the optimal targets to minimize on-target/off-tumor toxicity. Tumor escape via antigen loss and intrinsic heterogeneity is a further hurdle. TROP2, GD2, ROR1, MUC1 and EpCAM are promising targets. Persistence and trafficking to tumor cells may be enhanced by the implementation of CARs with a chemokine receptor and/or constitutively activated interleukin receptors. Fourth-generation CARs (TRUCKs) may redirect T-cells for universal cytokine-mediated killing. Combinatorial approaches and the application of CARs to other immune cells could revert the suppressive immune environment that characterizes solid neoplasms.

CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress / C. Corti, K. Venetis, E. Sajjadi, L. Zattoni, G. Curigliano, N. Fusco. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - 31:6 (Special issue)(2022 Jun 03), pp. 593-605. [10.1080/13543784.2022.2054326]

CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress

C. Corti
Primo
;
K. Venetis;E. Sajjadi;L. Zattoni;G. Curigliano
Penultimo
;
N. Fusco
Ultimo
2022

Abstract

Introduction: . Most breast cancer-related deaths arise from triple-negative breast cancer (TNBC). Molecular heterogeneity, aggressiveness and the lack of effective therapies are major hurdles to therapeutic progress. Chimeric antigen receptor (CAR)-T cells have emerged as a promising immunotherapeutic strategy in TNBC. This approach combines the antigen specificity of an antibody with the effector function of T cells. Areas covered: This review examines the opportunities provided by CAR-T cell therapies in solid tumors. Emerging targets, ongoing clinical trials, and prospective clinical implications in TNBC are considered later. An emphasis is placed on the key challenges and possible solutions for this therapeutic approach. Expert opinion: A challenge for CAR-T cell therapy is the selection of the optimal targets to minimize on-target/off-tumor toxicity. Tumor escape via antigen loss and intrinsic heterogeneity is a further hurdle. TROP2, GD2, ROR1, MUC1 and EpCAM are promising targets. Persistence and trafficking to tumor cells may be enhanced by the implementation of CARs with a chemokine receptor and/or constitutively activated interleukin receptors. Fourth-generation CARs (TRUCKs) may redirect T-cells for universal cytokine-mediated killing. Combinatorial approaches and the application of CARs to other immune cells could revert the suppressive immune environment that characterizes solid neoplasms.
CAR-T cell; breast cancer; clinical trials; drug discovery; drug targets; solid tumors; translational; triple negative breast cancer;
Settore MED/08 - Anatomia Patologica
Settore MED/06 - Oncologia Medica
3-giu-2022
21-mar-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
Revised-CART-TNBC.pdf

Open Access dal 04/06/2023

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 442.22 kB
Formato Adobe PDF
442.22 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/918132
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 26
social impact